The Cost-Effectiveness of Bendamustine-Rituximab (Ben-R) Versus R-Chop for the First Line Treatment of Patients with Indolent Non-Hodgkin’s Lymphoma (Inhl) in Colombia
Abstract
Authors
EA Wehler S Kowal JG Ariza C Zambrano JA de Anda P Anaya J Munakata L Gonzalez